Streetbeat News

Products Services

SCLX

Scilex Holding Company announced that the State of Indiana Medicaid will add Elyxyb, a drug developed by the company, to its Preferred Drug List effective from October 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 1:03 pm

TAK

Takeda Pharmaceutical Company Limited (TAK) has received approval for its subcutaneous immunoglobulin plasma therapy, CUVITRU, in Japan. The approval is based on clinical studies conducted in Japan, Europe, and North America, confirming the efficacy and safety of CUVITRU for patients with agammaglobulinemia or hypogammaglobulinemia.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:45 pm

BPTS

NIO

RNAZ

Biophytis and Skyepharma have signed a partnership agreement for the production of Sarconeos, causing Biophytis' stock (BPTS) to rise by 45%. TransCode Therapeutics (RNAZ) announced positive pre-clinical Glioblastoma results with its lead therapeutic candidate, TTX-MC138, leading to a 30% increase in its stock. NIO Inc. (NIO) announced the closing of a US$1 billion convertible senior notes offering, resulting in an 8.5% decrease in its stock.

Portfolio Pulse from ryanfaloona@benzinga.com

September 25, 2023 | 12:41 pm

TSLA

Tesla Inc. is expanding its operations in Thailand, developing innovative manufacturing techniques, and advancing in the field of humanoid robotics. CEO Elon Musk met with Thailand's Prime Minister to discuss opportunities in the Thai EV sector. Tesla is also developing the Gigapress, a machine to reduce assembly time and costs. Furthermore, Tesla's humanoid bot, Optimus, is set to rely on neural networks and cameras, with plans to release the first bot by November.

Portfolio Pulse from Mohit Manghnani

September 25, 2023 | 12:41 pm

ENVX

Enovix Corp's shares are trading higher after the company announced that its batteries were selected for use in Accurate Meditech's blood pressure monitor. The device, running on Enovix's batteries, is expected to last more than four months on a single charge. The blood pressure monitor will be available at CVS, Walgreens, and Walmart beginning in the second half of 2024.

Portfolio Pulse from Adam Eckert

September 25, 2023 | 12:41 pm

RNAZ

TransCode Therapeutics announced positive pre-clinical gliblastoma results with its lead candidate, TTX-MC138, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:38 pm

NWGL

Nature Wood Group Limited (NASDAQ:NWGL) has announced a strategic cooperation with the Research Institute of Wood Industry, Chinese Academy of Forestry. The partnership will focus on the research and development of biomass supramolecular and biomass carbon electrode new materials. The collaboration aims to advance biomass carbon innovation and drive the development of sustainable batteries from renewable sources worldwide.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:35 pm

CHRS

Coherus BioSciences announced that the FDA issued a complete response letter for UDENYCA ONBODY Biologics License Application due to an ongoing review of inspection findings at a third-party filler. No issues with clinical efficacy, safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified. No additional clinical data or trials have been requested by the FDA. The company also announced the completion of Toripalimab FDA inspections.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:33 pm

LTRN

Lantern Pharma Inc. (NASDAQ:LTRN) has announced the first patient dosing in the Phase 1 clinical trial for LP-184, a potential therapy for advanced solid tumors. The drug, developed with Lantern's AI Platform, RADR®, has a global aggregate market potential of approximately $11-13 billion. The Phase 1 trial is assessing the safety and tolerability of escalating doses of LP-184 in patients with advanced solid tumors and recurrent high-grade gliomas. Lantern plans to advance LP-184 into additional clinical trials after the Phase 1 trial.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:32 pm

RNAZ

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced positive pre-clinical results for its lead therapeutic candidate, TTX-MC138, in treating glioblastoma multiforme (GBM) tumors. The candidate was delivered to brain tumors and effectively engaged its target. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit the oncogenic RNA, microRNA-10b. The company's first-in-human clinical trial with TTX-MC138 is open for enrollment and has dosed its first patient.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:31 pm